Samyang Biopharm USA, Inc is the new subsidiary of Samyang Biopharmaceuticals Corporation (Korea) and will focus on biologics development in oncology and rare disease. The company will seek late preclinical to Phase 1 antibody, antibody drug conjugate and recombinant proteins for global in-license to develop in the United States.
Helen Lee, M.D.PRESIDENT
Hyun Jung Helen Lee, MD, MHCM is a Gynecologist by training and has been working on the development of anti-cancer drugs for 15 years in Global, the US and the Asia. Prior to joining Samyang, she served as the Global Head of Solid Tumor Clinical Development at Shire in the US. She has held various executive positions at Baxalta, Eli Lilly and Pfizer. After graduating from Yonsei University College of Medicine, she completed her residency training at Severance Hospital, and later, earned her master's degree in Health Care Management at Harvard School of Public Health. Since 2016, She has served as Chief Strategy Officer (CSO) and Chief Medical Officer (CMO) at Samyang. The company named Hyun Jung Helen Lee as President of Samyang Biopharm USA in 2018 to lead Samyang’s effort in developing a drug pipeline comprised of drugs to treat select cancers and rare diseases.
Jeffery Lange, MBA, CPAVP, Business Development
Vice President of Business Development, Jeffery Lange is a business development and licensing professional with extensive experience in pharma and biotech in/out-licensing, joint ventures, mergers and acquisitions. Prior to joining Samyang Biopharm USA, he served as the Vice President of Business Development – Valuation and Structuring at Baxalta Inc. in the US. He has held various executive positions in business development, licensing and acquisitions, and strategic planning at Glenmark Pharmaceuticals, SciClone Pharmaceuticals and Novartis. He received a BBA in accounting from University of Iowa and an MBA with a specialization in Finance from The University of Chicago. He began serving as a vice president of Samyang Biopharm USA from, January 2019.
Sean D. McKenna, Ph.D.VP, Research
Sean McKenna received his Bachelor’s degree in biology at University of Massachusetts at Amherst, Ph.D. in biomedical science at University of Connecticut School of Medicine. Following his postdoctoral training at the Jackson Laboratory, Dr. McKenna worked for over twenty years at Serono and EMD Serono in roles of increasing responsibility, culminating as Senior Director of Protein Engineering and Antibody Technologies, where he was responsible for all biotherapeutic discovery activities within the US subsidiary. Highlights within his career include co-inventorship of the first effector-competent anti-PD-L1 antibody, Bavencio, currently approved in Merkel cell carcinoma and metastatic bladder carcinoma, as well as the development of M7824, a novel clinical stage bispecific PD-L1 and TGF-beta antagonist. Mr. McKenna joined Samyang Biopharm USA as the Vice President of Research in October 2018.
David Brooks, M.D., Ph.D.VP, Clinical Development
David Brooks, MD, PhD is Vice President of Clinical Development and Head of Rare Disease Development. After completing the MD/PhD program at Cornell/Sloan-Kettering David trained in Internal Medicine and Medical Genetics at the University of Pennsylvania and CHOP. David has over 15 years of oncology and rare disease drug development experience in translational, diagnostic and therapeutic positions of increasing responsibility at Merck, Shire, Tesaro and Astra Zeneca. Most recently David was Sr VP of Clinical Development at SesenBio leading clinical development for the successful Phase 3 trial of antibody toxin conjugate vicinium, a potent immune activator, in bladder cancer. David joined Samyang Biopharm USA in September 2019.